Company intelligence / Profile preview

BioSource Therapeutics

San Francisco, California, United States

Ownership: Private
Development stage: Other

Overview

BioSource Therapeutics was a biotechnology company focused on developing novel small molecule therapies for metabolic diseases, including type 2 diabetes and obesity. The company aimed to leverage its expertise in metabolic pathways to create oral alternatives to injectable peptide therapies. Despite its initial focus on high-demand indications like NASH and diabetes, the company ceased operations and is no longer active in the clinical development space. Its intellectual property and research were primarily centered on GPCR modulation and metabolic signaling.

Therapeutic areas: EndocrinologyGastroenterology
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on BioSource Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BioSource Therapeutics.

Explore the full profile